125 related articles for article (PubMed ID: 20501616)
1. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
Marchi E; Paoluzzi L; Scotto L; Seshan VE; Zain JM; Zinzani PL; O'Connor OA
Clin Cancer Res; 2010 Jul; 16(14):3648-58. PubMed ID: 20501616
[TBL] [Abstract][Full Text] [Related]
2. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
[TBL] [Abstract][Full Text] [Related]
4. Pralatrexate (Folotyn).
Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
[TBL] [Abstract][Full Text] [Related]
5. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
Shi WY; Wang L; Xiao D; Yao Y; Yang F; Jiang XX; Leboeuf C; Janin A; Chen SJ; Zhao WL
Ann Hematol; 2011 Jan; 90(1):53-8. PubMed ID: 20617436
[TBL] [Abstract][Full Text] [Related]
10. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
O'Connor OA; Smith EA; Toner LE; Teruya-Feldstein J; Frankel S; Rolfe M; Wei X; Liu S; Marcucci G; Chan KK; Chanan-Khan A
Clin Cancer Res; 2006 May; 12(9):2902-11. PubMed ID: 16675587
[TBL] [Abstract][Full Text] [Related]
11. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Molina JR
IDrugs; 2008 Jul; 11(7):508-21. PubMed ID: 18600598
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Foss FM
Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
Hamner JB; Dickson PV; Sims TL; Zhou J; Spence Y; Ng CY; Davidoff AM
Surgery; 2007 Aug; 142(2):185-91. PubMed ID: 17689684
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
16. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
[TBL] [Abstract][Full Text] [Related]
17. Pralatrexate: an emerging new agent with activity in T-cell lymphomas.
O'Connor OA
Curr Opin Oncol; 2006 Nov; 18(6):591-7. PubMed ID: 16988580
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
19. Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
Weinkauf M; Hutter G; Zimmermann Y; Hartmann E; Rosenwald A; Dreyling M
Talanta; 2010 Feb; 80(4):1539-44. PubMed ID: 20082812
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]